Highlights Radiopharm Theranostics Limited

Equities

RAD

AU0000181851

Market Closed - Australian S.E. Other stock markets 02:10:50 2024-07-05 am EDT			5-day change	1st Jan Change
0.035 ^AUD	0.00%		-7.89%	-52.70%

Jul. 02	Radiopharm Theranostics Ends Share Subscription, Purchase Agreements with Lind Global	MT
Jun. 25	Radiopharm Theranostics Raises AU$70 Million to Fund Clinical Programs; Shares Jump 24%	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Radiopharm Theranostics Ends Share Subscription, Purchase Agreements with Lind Global	Jul. 01	MT
Radiopharm Theranostics Raises AU$70 Million to Fund Clinical Programs; Shares Jump 24%	Jun. 24	MT
US Radiopharmaceutical Firm to Invest Up to AU$18 Million into Radiopharm Theranostics	Jun. 19	MT
Radiopharm Theranostics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Radiopharm Theranostics Secures Ethics Approval for Second Lung Cancer Trial Site	Dec. 26	MT
Radiopharm Theranostics to Start Phase One Lung Cancer Therapy Trial	Dec. 25	MT
Radiopharm Theranostics Secures AU$5 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 4%	Nov. 20	MT
Radiopharm Theranostics Secures US FDA Approval for Phase 1 Pancreatic Cancer Diagnostic Trial	23-10-17	MT
Radiopharm Theranostics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Radiopharm Theranostics Secures US FDA Guidance for Clinical Trial of Imaging Drug in Brain Metastasis	23-05-29	MT
Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer	23-05-09	CI
Radiopharm Theranostics Receives US FDA Orphan Drug Designation for Pancreatic Cancer Medication	23-05-09	MT
Radiopharm Theranostics Receives AU$1.6 Million R&D Tax Refund; Shares Fall 3%	23-03-27	MT
Radiopharm Theranostics Limited and GenesisCare to Develop Novel Radiopharmaceuticals	23-03-26	CI
Radiopharm Theranostics Acquiring Pharma15 for AU$6 Million	23-03-03	MT
Radiopharm Theranostics Limited entered into a binding agreement to acquire Pharma15 Corporation.	23-03-02	CI
Radiopharm Theranostics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-28	CI
Radiopharm Theranostics Starts NASDAQ Listing Process	23-02-14	MT
Radiopharm Theranostics Secures Investigational New Drug Approval From US FDA for Imaging Drug; Shares Rise 5%	22-12-29	MT
Radiopharm Theranostics Receives US Food and Drug Administration Investigational New Drug Application Approval for Its V6 Integrin Technology	22-12-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Radiopharm Theranostics Limited

Equities

RAD

AU0000181851

Highlights

Filters